Concepedia

John F. Kurland

JF

39

Publications

5.9K

Citations

25

H-Index

1980

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Bristol-Myers Squibb (United States)

The University of Texas MD Anderson Cancer Center

AstraZeneca (United States)

Sidney Kimmel Comprehensive Cancer Center

John F. Kurland is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

1980–2025

39

Publications

39

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.3K citations · Full text

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 986 citations

, , +15

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma et al. · Journal of Clinical Oncology · 2016 · 839 citations · Full text

Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity

Anupama Munshi, John F. Kurland, Takashi Nishikawa et al. · Clinical Cancer Research · 2005 · 346 citations · Full text

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Toni K. Choueiri, Mayer Fishman, Bernard Escudier et al. · Clinical Cancer Research · 2016 · 290 citations · Full text

Rows per page

1–5 of 39